Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection

  • Authors:
    • Ming‑Yii Huang
    • Chun‑Ming Huang
    • Hsiang‑Lin Tsai
    • Ching‑Wen Huang
    • Hui‑Min Hsieh
    • Yung‑Sung Yeh
    • Jeng‑Yih Wu
    • Wen‑Ming Wang
    • Jaw‑Yuan Wang
  • View Affiliations

  • Published online on: September 26, 2017     https://doi.org/10.3892/ol.2017.7073
  • Pages:6754-6762
Metrics: PDF 0 views | HTML 0 views
0

Abstract

The present study aimed to demonstrate the potential advantage of oral uracil‑tegafur (UFUR)/leucovorin (LV) as the subsequent therapy in patients with stage III colon cancer following adjuvant LV, 5‑fluorouracil and oxaliplatin (FOLFOX4) chemotherapy. Of a total 143 patients, 62 patients received only FOLFOX adjuvant chemotherapy (FOLFOX4 biweekly x 12 cycles for 6 months), and 81 patients received FOLFOXU adjuvant treatment (which consisted of FOLFOX4 biweekly x 12 cycles for 6 months followed by oral UFUR/LV for an additional 6 months). The 3‑year disease‑free survival (DFS) rate of the FOLFOXU group was 74.3%; which was superior to that of the FOLFOX4 group (59.9%). The average DFS time of the FOLFOXU group was superior to that of the FOLFOX4 group (P=0.003). The 5‑year overall survival (OS) rate of the FOLFOXU group was 76.9%, which was also superior to that of the FOLFOX4 group (63.8%). The average OS time of patients in the FOLFOXU group was longer than that of the patients in the FOLFOX4 group (hazard ratio, 0.155; 95% confidence interval, 0.054‑0.450; P=0.001). In comparison to the FOLFOX regimen, the FOLFOXU regimen achieved a more favorable response and survival time without a significant increase of toxicities in patients with stage III colon cancer as the adjuvant chemotherapy.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Huang, M., Huang, C., Tsai, H., Huang, C., Hsieh, H., Yeh, Y. ... Wang, J. (2017). Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection. Oncology Letters, 14, 6754-6762. https://doi.org/10.3892/ol.2017.7073
MLA
Huang, M., Huang, C., Tsai, H., Huang, C., Hsieh, H., Yeh, Y., Wu, J., Wang, W., Wang, J."Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection". Oncology Letters 14.6 (2017): 6754-6762.
Chicago
Huang, M., Huang, C., Tsai, H., Huang, C., Hsieh, H., Yeh, Y., Wu, J., Wang, W., Wang, J."Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection". Oncology Letters 14, no. 6 (2017): 6754-6762. https://doi.org/10.3892/ol.2017.7073